Clinical-stage biopharmaceutical company, Achilles Therapeutics plc ( NASDAQ: ACHL ) received notice from Nasdaq that the company is not currently in compliance with the $1.00 minimum bid price requirement. The notice indicated that the company has 180 days, or until November 12, 2024, to regain compliance by having the closing bid price of the company’s ADSs meet or exceed $1.
00 per ADS for at least ten consecutive business days. The stock price gained 2.7% on Monday during pre-market trade.
More on Achilles Therapeutics Piper downgrades Achilles to neutral, cites latest data Seeking Alpha’s Quant Rating on Achilles Therapeutics Historical earnings data for Achilles Therapeutics Financial information for Achilles Therapeutics.